Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, December 2001, p. 3451-3455, Vol. 45, No. 12
Department of Drug Metabolism, Research
Center, Taisho Pharmaceutical Co., Ltd., 403, Saitama-shi, Saitama
330-8530, Japan
Received 24 March 2000/Returned for modification 15 November
2000/Accepted 17 September 2001
Triple therapy consisting of clarithromycin (CLR), lansoprazole
(LPZ), and amoxicillin (AMZ) is effective as eradication therapy for patients with peptic ulcer disease and Helicobacter
pylori infection. We evaluated the effects of LPZ and AMZ on the
uptake of [14C]CLR into the gastric tissue of rats. After
administration of [14C]CLR alone or in combination with
LPZ and AMZ, the distributions of [14C]CLR in the main
organs and gastrointestinal tissues were compared. LPZ and AMZ had no
effect on the distribution of [14C]CLR in any tissue
except gastric tissue. The concentration of radioactivity in gastric
tissue was several times higher when [14C]CLR was
administered orally together with LPZ than when it was administered
alone. The gastric emptying of [14C]CLR became smaller in
the case of the coadministration of LPZ. AMZ had no apparent influence
on the disposition of [14C]CLR. After the intravenous
administration of [14C]CLR, no effects of drug
coadministration were evident. In vitro uptake of
[14C]CLR into gastric tissue was enhanced in the case of
a high-pH environment. The uptake was not influenced by the
concurrent presence of LPZ and AMZ. These results suggest that the
penetration of [14C]CLR possibly depends on elevated
gastric pH, as gastric acid secretion was inhibited by LPZ, and this
may be a primary factor in explaining why the concentration of
[14C]CLR at the target site, gastric tissue, was enhanced
by the coadministration of LPZ.
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.12.3451-3455.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Effects of Lansoprazole and Amoxicillin on Uptake
of [14C]Clarithromycin into Gastric Tissue in
Rats
*
Corresponding author. Mailing address: Department of
Drug Metabolism, Research Center, Taisho Pharmaceutical Co., Ltd., 403, Yoshino-cho 1-chome, Saitama-shi, Saitama 330-8530, Japan. Phone: 81 48 663 1111. Fax: 81 48 652 7254. E-mail:
hiromi.endou{at}po.rd.taisho.co.jp.
This article has been cited by other articles:
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |